79 results on '"Daniele, B"'
Search Results
2. OC.12.4 PROGNOSTIC FACTORS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH LENVATINIB
3. 713P Pembrolizumab (Pembro) vs placebo (Pbo) as second-line treatment for sorafenib-treated advanced hepatocellular carcinoma (aHCC): 4.5-year follow-up from KEYNOTE-240
4. 1337P Implementation of precision oncology in clinical practice: A nationwide survey in Italy
5. SO-13 Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open-label, phase 2 KEYNOTE-224 study
6. Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
7. Intestinal cell models for investigating the uptake, metabolism and absorption of dietary nutrients and bioactive compounds
8. Translation and cross-cultural adaptation of the Childhood Bladder and Bowel Dysfunction Questionnaire (CBBDQ)
9. 302P Clinical implication of tissue re-biopsy in metastatic breast cancer (MBC) patients: A single centre retrospective analysis
10. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
11. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial
12. MA06.11 The Collision of Good Syndrome and Autoimmunity in Thymic Epithelial Tumors
13. Pattern of progression of intrahepatic cholangiocarcinoma impacts on survival: Implications for second-line trials
14. MA06.10 A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA
15. Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma: efficacy, safety and prognostic factors
16. Translation and cross-cultural adaptation of 14-item Mediterranean Diet Adherence Screener and low-fat diet adherence questionnaire
17. 1904P Clinical implications of distinct immunoprofiles in patients with thymic epithelial tumours and autoimmunity
18. 1901P Immunomodulatory role of multi-agent therapy in thymic epithelial tumours and severe immunological dysregulation
19. Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2)
20. Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240
21. Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)
22. Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients
23. Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240
24. Correction to: “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
25. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
26. The HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid
27. The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress
28. Bacterial cellulose/poly(3-hydroxybutyrate) composite membranes
29. Thermal behavior of cellulose acetate produced from homogeneous acetylation of bacterial cellulose
30. Carotenoid esters in foods - A review and practical directions on analysis and occurrence
31. Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial
32. Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study
33. Prognostic value of the neutrophil-to-lymphocyte ratio in advanced hepatocellular carcinoma: An exploratory analysis from the ARQ197-215 study
34. Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRiAlLdh)
35. Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + Bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRiAlLdh)
36. PACER – A multicentre, single-arm, two-stage, phase 2 study of panitumumab in patients with cetuximab-refractory metastatic colorectal cancer (mCRC)
37. Prognostic significance of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma: the ARQ197-215 study
38. Sorafenib in clinical practice: Pooled analysis of two prospective observational studies in hepatocellular carcinoma (HCC)
39. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma
40. Pressure Reducing Valve Characterization for Pipe System Management
41. Active Leakage Control with WDNetXL
42. Multicentric Prospective Study of Validation of Angiogenesis Polymorphisms in HCC Patients Treated with Sorafenib. Innovate Study
43. Optimal Design of District Metering Areas
44. Bioactive pigments from microalgae Phormidium autumnale
45. Prevalence of hepatitis B and C markers in a population of an urban university in Rio de Janeiro, Brazil: a cross-sectional study
46. Ramucirumab (RAM) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) Following First-Line Therapy with Sorafenib: Analyses from the Randomized Phase III REACH Study
47. Hepatocellular Carcinoma In Elderly Patients: final results of The Italian Cohort Of GIDEON (Global Investigational of therapeutic DEcisions in HCC and of its treatment with sorafeNib) Study
48. Safety and efficacy of sorafenib in stella study, a Multicenter, Observational, Phase IV Study In Italian Centers
49. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): results from a subgroup of patient from the MITO-16A-MANGO OV2A phase 4 trial
50. P-110 Hepatocellular carcinoma in elderly patients: Final results of the Italian cohort of GIDEON study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.